A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
Study Details
Study Description
Brief Summary
The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Amivantamab Monotherapy Participants will receive amivantamab monotherapy intravenously once weekly on Days 1 and 2 in Cycle 1 and on Days 1 and 15 from Cycle 2 onwards based on body weight. Each cycle is of 28 days. |
Drug: Amivantamab
Amivantamab will be administered intravenously.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (ORR) [Up to 1 year 10 months]
ORR is defined as the percentage of participants who achieve either partial response (PR) or complete response (CR), determined by investigator assessment using response criteria in solid tumors (RECIST) Version 1.1.
Secondary Outcome Measures
- Duration of Response (DOR) [Up to 1 year 10 months]
DoR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first.
- Disease Control Rate (DCR) [Up to 1 year 10 months]
DCR is defined as the percentage of participants achieving complete or partial response or stable disease of at least 11 weeks as defined by RECIST Version 1.1.
- Progression-free Survival (PFS) [Up to 1 year 10 months]
PFS is defined as the time from the date the first dose until the date of objective disease progression or death by any cause, whichever comes first, based on investigator review according to RECIST Version 1.1.
- Overall Survival (OS) [Up to 1 year 10 months]
OS is defined as the time from the date of the first dose until the date of death due to any cause.
- Number of Participants with of Adverse Events [Up to 1 year 10 months]
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.
- Number of Participants with Abnormalities in Clinical Laboratory Assessments [Up to 1 year 10 months]
Number of participants with abnormalities in clinical laboratory tests including serum chemistry and hematology) will be reported.
- Number of Participants with Abnormalities in Vital Signs [Up to 1 year 10 months]
Number of participants with abnormalities in vital signs (including temperature, pulse/heart rate, and blood pressure) will be reported.
- Maximum Serum Concentration (Cmax) of Amivantamab [Up to 1 year 10 months]
Cmax is defined as maximum serum concentration of amivantamab.
- Time to Reach Maximum Serum Concentration (Tmax) of Amivantamab [Up to 1 year 10 months]
Tmax is defined as time to reach maximum serum concentration of amivantamab.
- Area Under the Serum Concentration-time Curve of Amivantamab from Time t1 to t2 (AUC[t1-t2]) [Up to 1 year 10 months]
AUC(t1-t2) is defined as the area under the serum concentration-time curve of amivantamab from time t1 to t2.
- Area Under the Concentration-time Curve of Amivantamab From Time Zero to End of Dosing Interval (AUCtau) [Up to 1 year 10 months]
AUCtau is the measure of the serum drug concentration of amivantamab from time zero to end of dosing interval.
- Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab [Up to 1 year 10 months]
Ctrough is defined as serum concentration immediately prior to the next dose administration (Ctrough) of amivantamab.
- Accumulation Ratio (R) [Up to 1 year 10 months]
R is calculated as area under the plasma concentration-time curve from time zero to 24 hours (AUC [0-24]) value at steady state divided by AUC (0-24) value after first dose.
- Number of Participants with Anti-amivantamab Antibodies [Up to 1 year 10 months]
Number of participants with anti-amivantamab antibodies will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant must have histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC) (fibrolamellar and mixed hepatocellular / cholangiocarcinoma subtypes are not eligible) based on pathology report, who have barcelona clinic liver cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach
-
Participant must have measurable disease according to response criteria in solid tumors (RECIST) Version 1.1. Selected target lesions must meet 1 of 2 criteria: 1) not previously treated with local therapy or 2) within the field of prior local therapy but with documented subsequent progression as per RECIST v1.1
-
Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Participant must have adequate organ and bone marrow function
-
A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Female participants should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility
Exclusion Criteria:
-
Participants with prior liver transplant, history of hepatic encephalopathy, portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging, or any current moderate or severe ascites as measured by physical examination that requires active paracentesis for control due to the underlying HCC
-
Participant has known allergies, hypersensitivity, or intolerance to excipients of amivantamab
-
Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary
-
Other clinically active liver disease of infectious origin
-
Participant has a history of clinically significant cardiovascular disease including, but not limited to: a. diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study treatment or any of the following within 6 months prior to the first dose of study treatment: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as nonobstructive catheter-associated clots, are not exclusionary; b. prolonged corrected QT interval using Fridericia's formula (QTcF) greater than (>)480 millisecond (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); c. uncontrolled (persistent) hypertension: systolic blood pressure
160 mm Hg; diastolic blood pressure >100 millimeter of mercury (mm Hg), or congestive heart failure (CHF) defined as New York Heart Association (NYHA) class III/IV or hospitalization for CHF (any NYHA class) within 6 months of study enrollment; d. pericarditis/clinically significant pericardial effusion; e. myocarditis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Cancer Hospital | Beijing | China | 100142 | |
| 2 | The First Hospital of Jilin University | Chang Chun Shi | China | 130021 | |
| 3 | The Third Xiangya Hospital, Central South University | Changsha | China | 410013 | |
| 4 | West China Hospital | Chengdu | China | 610041 | |
| 5 | Chongqing Cancer Hospital | Chong Qing | China | 400033 | |
| 6 | The Second Affiliated Hospital of Dalian Medical University | Dalian | China | 116023 | |
| 7 | Mengchao Hepatobiliary Hospital of Fujian Medical University | Fu Zhou Shi | China | 350025 | |
| 8 | 900 Hospital of the Joint Logistics Team of the Chinese PLA | Fuzhou | China | 350025 | |
| 9 | Nanfang Hospital | Guang Zhou Shi | China | 510515 | |
| 10 | Zhejiang University First Hospital | Hang Zhou Shi | China | 310003 | |
| 11 | Zhejiang Cancer Hospital | Hangzhou | China | 310022 | |
| 12 | The 1st affiliated hospital of Anhui Medical University | Hefei | China | 230022 | |
| 13 | The Second Affiliatde Hospital To Nanchang University | Nan Chang Shi | China | 330030 | |
| 14 | Fudan University Shanghai Cancer Center | Shanghai | China | 200032 | |
| 15 | Union Hospital Tongji Medical College of Huazhong University of Science and Technology | Wuhan | China | 430030 | |
| 16 | Digestive Disease Hospital of Xi'An International Medical Center Hospital | Xi'an | China | 710100 |
Sponsors and Collaborators
- Janssen Research & Development, LLC
Investigators
- Study Director: Janssen Research & Development, LLC Clinical trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR109249
- 61186372HCC2001